

IN THE CLAIMS

Please amend the claims as follows:

1. (currently amended) An extended or controlled release encapsulated product, comprising:

a) at least one active ingredient comprising a psychotropic;

b) at least one erodible polymer selected from the group consisting of sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose ethyl cellulose, cellulose acetate methyl carbamate, methylcarbamate, polydiethylaminomethylstyrene, cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose alkanylate, monoalkenytes, dialkenytes, trialkenytes, mono-, di- and tri- arolyates, cellulose trivalerate, cellulose trioctanoate, cellulose ~~tripionate~~ tripropionate, cellulose diesters, cellulose disuccinate, cellulose acetate valerate, cellulose acetaldehyde, dimethylcellulose acetate, cellulose dimethylaminoacetate, semipermeable sulfonated polystyrenes, semipermeable styrenes, and mixtures thereof; and

c) at least one lubricating material; and

d) wherein said product is in the form of a caplet having a diameter from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters.

2. (canceled)

3. (canceled)

4. (canceled)

5. (canceled)

6. (original) The extended or controlled release encapsulated product of claim 1 wherein said lubricating material is selected from the group consisting of: fats, emulsifiers, waxes, magnesium stearate, calcium stearate, talc, starches, silicon dioxide, and mixtures thereof.

7. (original) The extended or controlled release encapsulated product of claim 1 wherein said diameter is about 3 millimeters and said length is about 3 millimeters.

8. (original) The extended or controlled release encapsulated product of claim 1 wherein said product provides controlled release of said active ingredient.

9. (original) The extended or controlled release encapsulated product of claim 1 wherein the product is coated with a polymeric material.

10. (original) The extended or controlled release encapsulated product of claim 1 wherein the product is shaped in a manner to have a crown which has a thinner polymer coating than the rest of the caplet.

11. (canceled)

12. (canceled)

13. (canceled)

14. (withdrawn from consideration) The encapsulated product of claim 13, wherein said psychotropic is a anti-anxiety therapeutic.

15. (withdrawn from consideration) The encapsulated product of claim 13, wherein said psychotropic is an insomnia therapeutic.

16. (currently amended) The encapsulated product of claim 1  
~~13~~, wherein said psychotropic is an antidepressant.

17. (original) The encapsulated product of claim 16, wherein said antidepressant is selected from the group consisting of Fluoxetine HCl, Paroxetine HCl, Sertraline HCl, and Venlafaxine HCl, Amitriptyline, Nortriptyline, Imipramine, Desipramine, Doxepin, Trimipramine, Clomipramine, Protriptyline, Amoxapine,

Maprotiline, Phenelzine, Tranylcypromine, Fluvoxamine, Venlafaxine, Trazodone, Nefazodone, Mirtazapine, Bupropion, or mixtures thereof.

18. (withdrawn from consideration) The encapsulated product of claim 17, wherein said pharmaceutical is Fluoxetine HCl.

19. (Currently amended, withdrawn from consideration) The encapsulated product of claim ~~12~~ 1, wherein said pharmaceutical is a gastrointestinal therapeutic.

20. (withdrawn from consideration) The encapsulated product of claim 19, wherein said gastrointestinal therapeutic is a ulcer therapeutic.

21. (withdrawn from consideration) The encapsulated product of claim 20, wherein said ulcer therapeutic is selected from the group consisting of Omeprazole, Lansoprazole, Ranitidine HCl, Famotidine, Nizatidine, Teprenone, Cimetidine, Rabeprazole sodium, Sulpiride, or mixtures thereof.

22. (withdrawn from consideration) The encapsulated product of claim 21, wherein said ulcer therapeutic is Omeprazole.

23. (withdrawn from consideration) The encapsulated product of

claim 19, wherein said gastrointestinal therapeutic is a anti-emetic.

24. (withdrawn from consideration) The encapsulated product of claim 23, wherein said anti-emetic is selected from the group consisting of Ondansetron HCl, Granisetron HCl, dimenhydrinate, Tropisetron, Dolasetron mesylate, Cisapride, Sulfasalazine, Balsalazide, Infliximab, or mixtures thereof.

25. (withdrawn from consideration) The encapsulated product of claim 24, wherein said anti-emetic is dimenhydrinate.

26. (withdrawn from consideration) The encapsulated product of claim 19, wherein said gastrointestinal therapeutic is a anti-diarrheal therapeutic.

27. (withdrawn from consideration) The encapsulated product of claim 26, wherein said anti-diarrheal therapeutic is selected from the group consisting of Loperamide HCl, diphenoxylate, codeine phosphate, camphorated opium tincture, or mixtures thereof.

28. (withdrawn from consideration) The encapsulated product of claim 27, wherein said anti-diarrheal therapeutic is Loperamide HCl

29. (currently amended) The encapsulated product of claim ~~12~~  
1, wherein said pharmaceutical is a migraine therapeutic.

30. (original) The encapsulated product of claim 29, wherein  
said migraine therapeutic is selected from the group consisting of  
sumatriptan succinate, amitriptyline, methysergide, propranolol,  
valproate, verapamil, dihydroergotamine, ergotamine,  
metoclopramide, naratriptan, prochlorperazine, rizatriptan  
benzoate, zolmitriptan, eletriptan, acetaminophen, aspirin,  
NSAID's, opioids, or mixtures thereof.

31. (withdrawn from consideration) The encapsulated product of  
claim 30, wherein said migraine therapeutic is sumatriptan  
succinate.

32. (withdrawn from consideration) The encapsulated product of  
claim 12, wherein said pharmaceutical is a therapeutic for the  
treatment of hypertension.

33. (withdrawn from consideration) The encapsulated product of  
claim 32, wherein said therapeutic is selected from the group  
consisting of nifedipine, amlodipine besylate, losartan potassium,

lisinopril, felodipine, benazepril HCl, ramipril, irbesartan, verapamil HCl, bisoprolol fumarate and hydrochlorothiazide, amlodipine and benazepril HCl, clonidine, candesartan, cilexetil, diltiazem, nicardipine, imidapril, trandolapril, eprosartan mesylate, nilvadipine, verapamil HCl, temocapril, prazosin HCl, isradipine, cilazapril, celiprolol, bisoprolol, betazolol HCl, ramipril, nisoldipine, lisinopril, trandolapril, and nisoldipine.

34. (withdrawn from consideration) The encapsulated product of claim 33, wherein said therapeutic is nifedipine.

35. (withdrawn from consideration) A pulsating release encapsulated product, comprising:

- a) at least one active ingredient;
- b) at least two erodible polymers, each of said erodible polymers having a different rate of dissolution or dissolving at a different pH; and
- c) at least one lubricating material; and
- d) wherein said product is in the form of a caplet having a diameter from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters.

36. (withdrawn from consideration) The pulsating release

encapsulated product of claim 35 wherein said erodible polymer is a water soluble polymer.

37. (withdrawn from consideration) The pulsating release encapsulated product of claim 36 wherein said water soluble polymer is selected from the group consisting of sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, propylene glycol alginate, sodium alginate, carboxymethyl cellulose and mixtures thereof.

38. (withdrawn from consideration) The pulsating release encapsulated product of claim 35 wherein said erodible polymer is a water insoluble polymer.

39. (withdrawn from consideration) The pulsating release encapsulated product of claim 38 wherein said water insoluble polymer is selected from the group consisting of cellulose acetate, ethyl cellulose, cellulose acetate methyl carbamate, methylcarbamate, polydiethylaminomethylstyrene, ethyl cellulose, cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose alkanylate, monoalkenytes, dialkenytes, trialkenytes, mono-, di- and tri-aroylates, cellulose trivalerate, cellulose trioctanoate, cellulose tripionate, cellulose diesters, cellulose

disuccinate, cellulose acetate valerate, cellulose acetaldehyde, dimethylcellulose acetate, cellulose dimethylaminoacetate, semipermeable sulfonated polystyrenes, semipermeable styrenes, and mixtures thereof.

40. (withdrawn from consideration) The pulsating release encapsulated product of claim 35 wherein said lubricating material is selected from the group consisting of: fats, emulsifiers, waxes, magnesium stearate, calcium stearate, talc, starches, silicon dioxide, and mixtures thereof.

41. (withdrawn from consideration) The pulsating release encapsulated product of claim 35 wherein said diameter is about 3 millimeters and said length is about 3 millimeters.

42. (withdrawn from consideration) The pulsating release encapsulated product of claim 35 wherein said product provides controlled release of said active ingredient.

43. (withdrawn from consideration) The pulsating release encapsulated product of claim 35 wherein the product is coated with a polymeric material.

44. (withdrawn from consideration) The pulsating release encapsulated product of claim 35 wherein the product is shaped in a manner to have a crown which has a thinner polymer coating than the rest of the caplet.

45. (withdrawn from consideration) The pulsating release encapsulated product of claim 35 wherein said active ingredient is a pharmaceutical.

46. (withdrawn from consideration) The pulsating release product of claim 45 wherein said pharmaceutical is selected from the group consisting of: antitussives, antihistamines, decongestants, alkaloids, mineral supplements, laxatives, antacids, ion exchange resins, anti-cholesterolemics, antiarrhythmics, antipyretics, analgesics, appetite suppressants, expectorants, anti-anxiety agents, anti-ulcer agents, anti-inflammatory substances, coronary dilators, cerebral dilators, peripheral vasodilators, anti-infectives, psychotropics, antimanicics, stimulants, gastrointestinal agents, sedatives, anti-diarrheal preparations, anti-anginal drugs, vasodialators, anti-hypertensive drugs, vasoconstrictors, migraine treatments, antibiotics, tranquilizers, anti-psychotics, antitumor drugs, anticoagulants, antithrombotic drugs, hypontics, anti-emetics, anti-nausants,

anti-convulsants, neuromuscular drugs, hyper- and hypoglycemic spasmodics, uterine relaxants, mineral and nutritional additives, antiobesity drugs, anabolic drugs, erythropoetic drugs, antiashmatics, cough suppressants, mucolytics, anti-uricemic drugs and mixtures thereof.

47. (withdrawn from consideration) A pulsating release product, comprising a capsule having a plurality of caplets, said caplets comprising:

- a) at least one active ingredient;
- b) at least one erodible polymer;
- c) at least one lubricating material; and
- d) wherein said caplet has a diameter from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters; and

wherein at least one of said plurality of caplets is prepared from an erodible polymer having a first dissolution rate, and at least another of said plurality of caplets is prepared from another erodible polymer having a second dissolution rate, and said first dissolution rate is not equal to said second dissolution rate.